U.S. Markets close in 1 hr 27 mins

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
48.50+1.86 (+3.99%)
As of 2:33PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close46.64
Open46.47
Bid49.02 x 800
Ask49.84 x 900
Day's Range46.47 - 51.20
52 Week Range25.43 - 53.49
Volume178,244
Avg. Volume120,223
Market Cap2.156B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.25
  • Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week
    Simply Wall St.

    Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week

    Celebrations may be in order for Kymera Therapeutics, Inc. (NASDAQ:KYMR) shareholders, with the analysts delivering a...

  • Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
    GlobeNewswire

    Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference

    WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020. A webcast of the pre-recorded fireside chat presentation has been made available ahead of the conference and can be accessed by clicking here and found under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. The webcast will remain available for 90 days.About Kymera Therapeutics Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.Contact:Investors@kymeratx.com Bruce Jacobs Chief Financial Officer +1 857.285.5300Christopher F. Brinzey Westwicke, an ICR Company for Kymera Therapeutics chris.brinzey@westwicke.com +1 339.970.2843media@kymeratx.comLissette L. Steele Verge Scientific Communications for Kymera Therapeutics lsteele@vergescientific.com +1 202.930.4762

  • What You Need To Know About Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Investor Composition
    Simply Wall St.

    What You Need To Know About Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Investor Composition

    The big shareholder groups in Kymera Therapeutics, Inc. (NASDAQ:KYMR) have power over the company. Insiders often own...